Pulse nav.journalClub Aktive Debatten Trends Entdecken Fragen Forschende

Download the App

Join discussions, follow papers, and never miss your next session.

Download on theApp Store

© Synapse Social LLC, 2026

Start Entdecken nav.journalClub Trends

⌘+K

February 27, 2026

Dupilumab Use in Severe Epidermolysis Bullosa Simplex

Key Points

The aim is to evaluate the effects of dupilumab in an infant with severe epidermolysis bullosa simplex.
Case report of an infant patient
Assessment of treatment response to dupilumab
Monitoring for adverse effects
Improvement in skin condition observed
Reduction in blister formation noted
No significant adverse effects reported

Abstract

This case report describes treatment with dupilumab in an infant patient with generalized severe epidermolysis bullosa simplex due to a pathogenic variant.

Like

Bookmark

Share

Like

Bookmark

Share

Dupilumab Use in Severe Epidermolysis Bullosa Simplex | Synapse

Cite This Study

Crespi et al. (Wed,) studied this question.

synapsesocial.com/papers/69a13571ed1d949a99abf550 https://doi.org/https://doi.org/10.1001/jamadermatol.2025.5754